NX005

NX005 is an investigational monoclonal antibody therapeutic program described as the lead asset of a company developing biologics for autoimmune disease, with preclinical data indicating it is designed to modulate pathogenic immune pathways implicated in autoimmunity rather than directly targeting tumors.[5] Publicly available summaries characterize NX005 as a monoclonal antibody drug candidate for autoimmune indications, but specific target, epitope, and detailed mechanism of action have not been disclosed in accessible sources, and it is distinct from similarly named C1q‑targeting antibody ANX005 that is in development for neurological and complement‑mediated disorders.[1][3] NX005 reportedly advanced into early‑stage clinical development but the associated program has since been discontinued at Phase 1, suggesting initial exploration in humans without progression to later‑stage efficacy trials in a defined autoimmune disease population.[5]